Nothing about us without us? Using public consensus for priority setting in Alzheimer's disease research.
Timothy Daly1,2
1Bioethics Program, FLACSO Argentina, Buenos Aires, Argentina.
Journal of Alzheimer'S Disease : JAD
|January 20, 2026
Summary
Engaging the public in Alzheimer's disease and related dementias research priority setting ensures studies address societal needs. This involvement makes research more impactful for those affected by these conditions.
Area of Science:
- Neuroscience
- Public Health
- Health Services Research
Background:
- Alzheimer's disease and related dementias (AD/ADRD) research requires public input for greater relevance.
- Current research priorities may not fully align with the needs of affected communities.
Purpose of the Study:
- To emphasize the necessity of public involvement in setting research priorities for AD/ADRD.
- To advocate for research questions that address societal concerns and values.
Main Methods:
- Review of current practices in research priority setting.
- Analysis of the impact of public engagement in health research.
Main Results:
- Public involvement in upstream consensus-building enhances research impact.
- Societal relevance is a critical factor for impactful AD/ADRD research.
Conclusions:
- Integrating public perspectives into AD/ADRD research priority setting is crucial.
- Future research should prioritize questions reflecting societal values and concerns.
More Related Videos
Related Concept Videos
01:29Documentation in Long-Term and Home Healthcare Setting
1.5K
Documentation in long-term care facilities and home healthcare settings is crucial for ensuring continuous, coordinated, and comprehensive care for patients. Each setting has its specific documentation processes and tools:
Long-Term Care Facilities
Long-Term Care Facilities
1.5K
01:26Alzheimer's Disease: Overview
1.7K
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
1.7K
01:22Alzheimer's Disease: Treatment
1.3K
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
1.3K
01:29Alzheimer Disease l: Introduction
21
Alzheimer disease is a chronic, progressive, and irreversible neurodegenerative disorder and the most common cause of dementia in older adults. It leads to gradual neuronal loss, causing cognitive decline, behavioral changes, and loss of functional independence.Risk Factors and EtiologyThe disease is multifactorial. Age is the strongest risk factor, with prevalence doubling every 5 years after age 65. Genetic factors include mutations in genes such as APP, PSEN1, and PSEN2, which are associated...
21